These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical criteria versus DNA diagnosis in heterozygous familial hypercholesterolemia: Is molecular diagnosis superior to clinical diagnosis? Schuster H; Luft FC Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):331-2. PubMed ID: 9514399 [No Abstract] [Full Text] [Related]
4. Identification and Management of Heterozygous Familial Hypercholesterolemia. Proceedings of a workshop. July 20-21, 1992. Am J Cardiol; 1993 Sep; 72(10):1D-84D. PubMed ID: 8105672 [No Abstract] [Full Text] [Related]
6. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409 [TBL] [Abstract][Full Text] [Related]
7. Identification of people with heterozygous familial hypercholesterolemia. Haase A; Goldberg AC Curr Opin Lipidol; 2012 Aug; 23(4):282-9. PubMed ID: 22801386 [TBL] [Abstract][Full Text] [Related]
8. Treatment of children with heterozygous familial hypercholesterolemia. Reiner Ž; Sahebkar A Int J Cardiol; 2020 Apr; 304():177-178. PubMed ID: 31735366 [No Abstract] [Full Text] [Related]
9. Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196). Alkhouri N Expert Opin Investig Drugs; 2020 Feb; 29(2):99-101. PubMed ID: 31868036 [No Abstract] [Full Text] [Related]
10. Multiple Ligation-dependent Probe Amplification Along with Whole Exome Sequencing Should be Required for the Diagnosis of Structural Heterozygous Familial Hypercholesteremia. Saotome M; Maekawa Y Intern Med; 2022; 61(19):2829-2830. PubMed ID: 36184533 [No Abstract] [Full Text] [Related]
11. Familial hypercholesterolemia. There is a need for early detection and treatment. Bilheimer DW JAMA; 1987 Jan; 257(1):69-70. PubMed ID: 3783906 [No Abstract] [Full Text] [Related]
12. Management of familial heterozygous hypercholesterolemia. Position paper of the Polish Lipid Expert Forum. Rynkiewicz A; Cybulska B; Banach M; Filipiak KJ; Guzik T; Idzior-Waluś B; Imiela J; Jankowski P; Kłosiewicz-Latoszek L; Limon J; Myśliwiec M; Opolski G; Steciwko A; Stępińska J; Zdrojewski T Pol Arch Med Wewn; 2013; 123(1-2):7-10. PubMed ID: 23449188 [No Abstract] [Full Text] [Related]
18. Identification and management of heterozygous familial hypercholesterolemia: summary and recommendations from an NHLBI workshop. Bild DE; Williams RR; Brewer HB; Herd JA; Pearson TA; Stein E Am J Cardiol; 1993 Sep; 72(10):1D-5D. PubMed ID: 8105671 [TBL] [Abstract][Full Text] [Related]
19. [Familial hypercholesterolemia: A largely underestimated cardiovascular risk]. Ferrières J; Bruckert É; Béliard S; Rabès JP; Farnier M; Krempf M; Cariou B; Danchin N Ann Cardiol Angeiol (Paris); 2018 Feb; 67(1):1-8. PubMed ID: 28576280 [TBL] [Abstract][Full Text] [Related]